Lannett gets FDA OK for generic Marinol
The Food and Drug Administration has approved Lannett’s generic Marinol (dronabinol capsules). The drug is indicated to treat loss of appetite in patients with AIDS who have lost weight and to treat nausea and vomiting induced by chemotherapy.
Lannett’s generic will be available in 2.5-, 5- and 10-mg dosage strengths. The product had a market size of roughly $120 million for the 12 months ended March 2018, according to IQVIA data.
“The approval of dronabinol capsules adds to our sizeable portfolio of near-term product opportunities," Lannett CEO Tim Crew said. “We expect to commence marketing several products including dronabinol capsules over the course of this year. Currently, only a handful of manufacturers supply generic dronabinol capsules to the U.S. market."
Lannett’s generic will be available in 2.5-, 5- and 10-mg dosage strengths. The product had a market size of roughly $120 million for the 12 months ended March 2018, according to IQVIA data.
“The approval of dronabinol capsules adds to our sizeable portfolio of near-term product opportunities," Lannett CEO Tim Crew said. “We expect to commence marketing several products including dronabinol capsules over the course of this year. Currently, only a handful of manufacturers supply generic dronabinol capsules to the U.S. market."